Sophiris Bio, Inc.
SPHS
SPHS was delisted on the 11th of March, 2020.
31 hedge funds and large institutions have $2.15M invested in Sophiris Bio, Inc. in 2018 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 9 increasing their positions, 5 reducing their positions, and 8 closing their positions.
80% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 5
11% less funds holding
Funds holding: 35 → 31 (-4)
25% less call options, than puts
Call options by funds: $21K | Put options by funds: $28K
50% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 8
68% less capital invested
Capital invested by funds: $6.73M → $2.15M (-$4.58M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$122K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$86.9K |
| 3 |
VF
Virtu Financial
New York
|
+$70.5K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$62.1K |
| 5 |
HP
Hikari Power
Tokyo,
Japan
|
+$60.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ARTA
A.R.T. Advisors
New York
|
-$123K |
| 2 |
AAMU
Amundi Asset Management US
Boston,
Massachusetts
|
-$66K |
| 3 |
CIBC World Market
Toronto,
Ontario, Canada
|
-$32K |
| 4 |
IP
Intellectus Partners
San Francisco,
California
|
-$24K |
| 5 |
Bank of New York Mellon
New York
|
-$19.7K |
SPHS Hedge Fund Activity: Q4 2018 in Review
31 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in Sophiris Bio, Inc. (SPHS) for Q4 2018, worth a combined $2.15M — down 68% from $6.73M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of SPHS and 4 opened new positions — a net loss of 4 holders — while 5 trimmed existing stakes and 9 added.
The largest buyer was Oxford Asset Management, opening a new position worth an estimated $122K. The largest seller was A.R.T. Advisors, exiting entirely with an estimated $123K sold.
- 31 institutional investors held Sophiris Bio, Inc. (SPHS) as of Q4 2018, down from 35 in Q3 2018.
- Funds reported $2.15M of Sophiris Bio, Inc. stock for Q4 2018, down 68% quarter-over-quarter.
- 4 funds opened new Sophiris Bio, Inc. positions in Q4 2018 and 8 closed out, a net change of -4 holders.
- The largest Sophiris Bio, Inc. buyer in Q4 2018 was Oxford Asset Management, an estimated $122K added.
- The largest Sophiris Bio, Inc. seller in Q4 2018 was A.R.T. Advisors, an estimated $123K sold.
Based on aggregated 13F filings for Q4 2018.